Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.

Area of Science:

• Biochemistry
• Pharmacology
• Drug Discovery

Background:

• Cytochrome P450 (CYP) enzymes are crucial for drug metabolism, and their inactivation mechanisms are critical to understand for safe drug development.
• Small molecules can inhibit CYP activity through apoprotein adduct formation or heme modification, impacting drug efficacy and safety.
• Previous studies showed raloxifene and N-(1-pyrene) iodoacetamide (PIA) alkylated CYP3A4, but only raloxifene affected activity, indicating a complex relationship between alkylation and function.

Purpose of the Study:

• To investigate the compound-dependent disconnect between CYP3A4 protein alkylation and loss of enzymatic activity.
• To elucidate the mechanisms underlying time-dependent inhibition of CYP3A4 by comparing two cysteine-selective alkylating agents: PIA and pyrene maleimide (PM).
• To understand how variations in electrophile structure influence CYP3A4 biochemical behavior and the interpretation of inactivation experiments.

Main Methods:

• Assessed the impact of PIA and PM on CYP3A4's enzymatic activity over time.
• Measured carbon monoxide (CO) binding capacity to evaluate effects on the heme environment.
• Quantified intact heme content to determine if heme was modified or destroyed.
• Utilized differential scanning fluorescence to assess changes in protein conformation and aggregation propensity.

Main Results:

• Pyrene maleimide (PM) caused a significant time-dependent loss of CYP3A4 enzymatic activity, while PIA did not.
• Differential effects on enzymatic activity correlated with changes in CO binding capacity, suggesting PM disrupts the active site more profoundly.
• Neither PIA nor PM altered intact heme concentrations, indicating heme was not directly modified or destroyed.
• PM treatment shifted the protein aggregation onset temperature, indicating PM induces conformational changes not seen with PIA.

Conclusions:

• Apoprotein alkylation of CYP3A4 can variably affect catalytic activity, CO binding, and protein conformation in a compound-dependent manner.
• The study underscores the need for careful interpretation of experimental data when characterizing P450 inactivation mechanisms.
• Understanding these subtle compound-specific differences is crucial for predicting and mitigating drug-induced P450 inhibition in drug discovery.